MarketBeat cites USD 26.50 target for OrthoPediatrics stock

Published on 10/20/2026 at 21:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Seven brokers support a Moderate Buy view with a USD 26.50 target. OrthoPediatrics stock costs EUR 20.60 on October 20, 2026 at Lang & Schwarz.

Analyst target and earnings date

MarketBeat reported a seven-broker Moderate Buy consensus and a USD 26.50 target on October 15, 2026.
OrthoPediatrics generated USD 70.51 million in second-quarter 2026 revenue, up 15.00 percent year over year.
OrthoPediatrics stock costs EUR 20.60 at Lang & Schwarz on October 20, 2026 at 9:17 p.m. CEST.
The company scheduled third-quarter 2026 results for October 27, 2026.

KIDS, US68752L1008, Illustration mit AI erstellt.

MarketBeat reported on October 15, 2026 that seven brokerages held a Moderate Buy consensus for OrthoPediatrics, with a USD 26.50 average 12-month target and five buy, one hold and one sell rating. The target is 14.72 percent above the USD 23.10 Nasdaq quote at 3:21 p.m. EDT on October 20, 2026. OrthoPediatrics was trading at EUR 20.60 at Lang & Schwarz on October 20, 2026 at 9:17 p.m. CEST.

Revenue growth remains visible

The latest reported quarter delivered a stronger operating picture than the share price alone suggests. In the second quarter of 2026, revenue reached USD 70.51 million, an increase of 15.00 percent from the second quarter of 2025, according to The Globe and Mail. Trauma and deformity revenue rose 26.00 percent to USD 52.60 million, while scoliosis revenue declined 9.00 percent to USD 16.90 million.

Adjusted EBITDA reached USD 6.80 million in the second quarter of 2026, compared with USD 4.10 million a year earlier. Gross profit margin was 74.00 percent, up from 72.00 percent in the second quarter of 2025, while free cash flow usage improved 78.00 percent to USD 3.10 million.

Stock position and valuation

The Nasdaq quote placed OrthoPediatrics at USD 23.10 on October 20, 2026, against a 52-week range of USD 14.42 to USD 26.74. The stock was 13.61 percent below its 52-week high and 60.06 percent above its 52-week low. Its market capitalization was USD 603.10 million, and volume was 117,255 shares at the quoted time.

MarketBeat said the company had a price-to-earnings ratio of minus 13.24 and a negative net margin of 15.72 percent in its October 15, 2026 report. The negative valuation measure reflects the company's reported losses, while the current target discussion rests on expected growth rather than established earnings.

Next results arrive October 27

OrthoPediatrics is scheduled to report third-quarter 2026 results after the market closes on October 27, 2026, with the conference call set for 4:30 p.m. EDT, according to OrthoPediatrics. MarketBeat listed consensus expectations of USD 68.50 million in revenue and an adjusted loss of USD 0.2250 per share for that quarter on October 20, 2026.

Price stays below the yearly high

The combination of a USD 26.50 average target and a USD 26.74 52-week high leaves the coming results as the next concrete test for the growth narrative. Management's second-quarter figures included a raised full-year 2026 revenue outlook of USD 265 million to USD 269 million, according to The Globe and Mail.

OrthoPediatrics was trading at EUR 20.60 at Lang & Schwarz on October 20, 2026 at 9:17 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of OrthoPediatrics stock.